Venmax Drugs and Pharmaceuticals Ltd
Allotment of 7,53,334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation, 2015.
FUNDRAISE
▲ Positive Development
LOW RISK
📅 Filed on BSE: 30 Jul 2026, 04:15 PM IST · BSE ID: 4bcc9264-f38f-4e5b-8d5c-e219393b3972
View Original BSE Filing (PDF)
💡
In Simple Terms
The company converted warrants into new shares, bringing in over Rs. 1.13 Crore.
🤖 AI Summary
- Venmax Drugs converts 7,53,334 warrants into equity shares.
- Non-promoter Dinesh Muddu Kotian exercised conversion rights.
- Company receives Rs. 1,13,00,010 from warrant exercise.
- Allotment increases paid-up capital to Rs. 14,48,39,290.
- Board approved allotment on July 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Allotted
7,53,334
Issue Price per Equity Share
Rs. 20/-
Face Value per Equity Share
Rs. 10/-
Premium per Equity Share
Rs. 10/-
Total Consideration Received
Rs. 1,13,00,010/-
New Paid-up Capital
Rs. 14,48,39,290/-
Total Equity Shares Post-Allotment
1,44,83,929
🏢 How This Affects the Company
The conversion of warrants has resulted in the inflow of Rs. 1,13,00,010, increasing the company's paid-up capital. This transaction impacts the equity structure by issuing new shares.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing shareholders regarding this warrant conversion.
👤
Who Is Affected
Existing shareholders are affected by a dilution of their percentage ownership due to the issuance of 7,53,334 new equity shares.
🔍
Management Signal
Management is executing its capital raising strategy through preferential allotment of warrants.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Confirmation of balance exercise price payment for remaining warrants.
Company's utilization of funds raised from warrant conversions.
Next financial results announcement for operational performance.
LOW RISK
Routine preferential allotment and conversion of warrants, a standard capital raising method.
💡 Investor Takeaway
Venmax Drugs completed the conversion of 7,53,334 warrants, raising Rs. 1,13,00,010. The company's paid-up capital now stands at Rs. 14,48,39,290.
⚖️ Strengths & Concerns
✅ Positives
- Received Rs. 1,13,00,010 from the conversion of 7,53,334 warrants at Rs. 20 per share.
- Increased paid-up share capital to Rs. 14,48,39,290 through the allotment of 7,53,334 equity shares.
📅 Company Track Record
Previous filings show Venmax Drugs has been actively converting warrants. In March 2026, 28,00,000 warrants were converted, raising Rs. 4.20 Crore. In July 2026, 21,47,665 warrants were converted, adding Rs. 3.22 Crore capital.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
How many equity shares did Venmax Drugs allot upon warrant conversion?
Venmax Drugs allotted 7,53,334 equity shares upon the conversion of warrants.
What was the total amount raised by Venmax Drugs from this warrant conversion?
The company raised Rs. 1,13,00,010/- from the conversion of 7,53,334 warrants.
Who was the allottee for the converted warrants in Venmax Drugs?
Dinesh Muddu Kotian, a Non-Promoter, was the allottee who converted 7,53,334 warrants.
What is the new paid-up capital of Venmax Drugs after this allotment?
Post allotment, the company's paid-up capital increased to Rs. 14,48,39,290/-.
What is the issue price for the equity shares issued upon warrant conversion?
The equity shares were issued at Rs. 20/- each, comprising a face value of Rs. 10/- and a premium of Rs. 10/-.
Questions based on this BSE filing only. For information purposes.